NK-92MI細(xì)胞

ATCC Number： CRL-2408?

相關(guān)**： 其他**

生長狀態(tài)： 懸浮生長，多細(xì)胞聚集

運輸方式： 凍存運輸

年限： 50 years

數(shù)量： 大量

細(xì)胞形態(tài)： **樣

細(xì)胞類型： 其他細(xì)胞類型

是否是腫瘤細(xì)胞： 1

物種來源： 人

Designations: NK-92MI

Depositors: Conkwest Inc.

NK-92MI細(xì)胞Biosafety Level: 2

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension, multicell aggregates

Organism: Homo sapiens deposited as human

Morphology: lymphoblast

Source: Disease: malignant non-Hodgkin's lymphoma

Cell Type: natural killer cell; NK cell;

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

DNA Profile (STR): D5S818: 12. 13

D13S317: 9, 12

D7S820: 10, 11

D16S539: 11, 12

vWA: 16, 18

THO1: 6, 9.3

TPOX: 8

CSF1PO: 11, 12

Amelogenin: X, Y

Age: 50 years

Gender: male

Ethnicity: NK-92MI細(xì)胞Caucasian

Comments: NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. NK-92MI is an interleukin-2 (IL-2) independent Natural Killer Cell line derived from the NK-92 (ATCC CRL-2407) cell line by transfection. The parental cells were transfected with human IL-2 cDNA in the retroviral MFG-hIL-2 vector by particle-mediated gene transfer. The transfection is stable, most likely due to integration of the vector into genomic DNA. The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays. NK-92 and derivative cell line NK-92MI have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. The parental IL-2 dependent cell line is available as CRL-2407 (NK-92). NK-92MI was shown to contain, express, and synthesize the hIL-2. A culture submitted to the ATCC in September of 1998 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline. The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.

Propagation: ATCC complete growth medium: The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; horse serum to a final concentration of 12.5%; fetal bovine serum to a final concentration of 12.5%.

Temperature: 37.0°C

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Subculturing: Protocol: NK-92MI細(xì)胞Cultures can be maintained by centrifuging cells and resuspending cell pellet in fresh medium at 2 - 3 X 105 viable cells/mL. Centrifugation and full replacement of culture medium may be performed for the first subcultures. Cultures can then be maintained by addition of fresh medium. Pipet the cells up and down on the back of the flask every 2-3 days to produce a single cell suspension. Maintain cell density between 2 X 10 5 and 1 X 10 6 viable cells/ml or use a 1:3 spilt ratio.

Preservation: Freeze medium: FBS, 90%; DMSO, 10%

Storage temperature: liquid nitrogen vapor phase

Related Products: recommended serum: ATCC 30-2020

recommended serum: ATCC 30-2040

parental cell line: ATCC CRL-2407 (EBV po

References: 38894: Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260

38969: Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666

40184: Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. NK-92MI細(xì)胞PubMed: 10417052